UroGen Pharma Ltd. (URGN)
Market Cap | 193.73M |
Revenue (ttm) | 64.36M |
Net Income (ttm) | -109.78M |
Shares Out | 23.09M |
EPS (ttm) | -4.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 46,137 |
Open | 8.29 |
Previous Close | 8.36 |
Day's Range | 8.05 - 8.55 |
52-Week Range | 4.85 - 12.63 |
Beta | 0.76 |
Analysts | Buy |
Price Target | 23.87 (+184.51%) |
Earnings Date | May 8, 2023 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma an... [Read more]
Financial Performance
In 2022, UroGen Pharma's revenue was $64.36 million, an increase of 33.96% compared to the previous year's $48.04 million. Losses were -$109.78 million, -0.94% less than in 2021.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $23.87, which is an increase of 184.51% from the latest price.
News

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda...

UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, t...

UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, a...

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, to...

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
SAN DIEGO--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today a...

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
SAN DIEGO--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced new data from the ...

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, t...

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, t...

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
PRINCETON, N.J.

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
PRINCETON, N.J.

UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
PRINCETON, N.J.

Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter...

UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma's JELMYTO® Admixture to 96 Hours Following Reconstitution
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...

UroGen Pharma Announces Upcoming 2022 Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...